Product development resource
Oral Strip Formulation Guide
An oral strip formula is a coupled system of active, film former, plasticizer, flavour or masking components and process conditions. Changing one part can alter strength, drying, disintegration and sensory performance.
Short answer
Start oral strip formulation with the active and intended product experience, then build the film system around those constraints. A practical formula must spread or form consistently, dry without unacceptable defects, release from the liner, survive cutting and handling, disintegrate as intended and taste acceptable. Ingredient percentages alone cannot establish that performance.
What each part of the formula does
| Formula element | Primary role | Trade-offs to watch |
|---|---|---|
| Active or functional ingredient | Delivers the product job | Payload, taste, particle behavior, stability |
| Film-forming polymer | Creates the matrix | Viscosity, strength, disintegration, drying |
| Plasticizer | Supports flexibility | Tack, moisture response, strength |
| Sweetener/flavour/masking system | Shapes oral acceptance | Added solids, aftertaste, release behavior |
| Surfactant or dispersing aid | Supports wetting or distribution | Foam, taste, compatibility |
| Saliva stimulant or disintegrant | Supports oral breakdown | Sensory intensity and matrix integrity |
Not every formula needs every category, and acceptable materials depend on product classification and target market.
A useful prototype strategy
Avoid changing many variables at once. Establish a control prototype, then vary the factor linked to the observed problem. If the film cracks, investigate solids, polymer-plasticizer balance, drying and conditioning rather than immediately adding flavour. If the active settles or creates visible variation, address particle or dispersion behavior before optimizing colour.
Record wet-mix observations, castability, drying behavior, web defects, release, thickness, mass, handling, disintegration, taste and residue for each version. This creates a development trail that can be transferred to a manufacturer.
Constraints that should stay visible
Dose and strip size define the available formulation space. Taste masking may compete with rapid disintegration. A more flexible film may become tackier under humidity. A faster-dissolving matrix may be less robust during converting. These tensions should be made explicit in the product brief.
Continue with payload feasibility and taste masking, then connect the selected system to the manufacturing process.
Formulation decisions in dependency order
| Decide or learn first | Then evaluate | Avoid locking too early |
|---|---|---|
| Active identity, grade and working dose | Solubility or dispersion, taste and stability | Final strip size |
| Desired serving and oral experience | Film area, thickness and breakdown target | Final flavour system |
| Polymer and solids direction | Castability, drying and mechanics | Commercial process settings |
| Sensory problem to solve | Masking approach and active release | Final colour or cosmetic finish |
| Product sensitivity | Pack barrier and stability plan | Printed commercial laminate |
Practical development guidance: this order reduces rework, but the exact sequence may change when a known process or transferred formula already exists.
Evidence and sources
Evidence guide: Published evidence — supported by the linked literature. · CoManufacturing experience — practical development observations, not universal specifications. · Supplier-specific — confirm with the supplier being evaluated. · Product-specific validation — prove with the actual formula, process, pack and market.
- Salawi, “An Insight into Preparatory Methods and Characterization of Orodispersible Film—A Review,” Pharmaceuticals 15 (2022): 844. doi:10.3390/ph15070844 · Full text
- Özakar and Özakar, “Current Overview of Oral Thin Films,” Turkish Journal of Pharmaceutical Sciences 18 (2021): 111–121. doi:10.4274/tjps.galenos.2020.76390 · Full text
- Ferlak, Guzenda and Osmałek, “Orodispersible Films—Current State of the Art, Limitations, Advances and Future Perspectives,” Pharmaceutics 15 (2023): 361. doi:10.3390/pharmaceutics15020361 · Full text